While several
methamphetamine- and
morphine-induced psychotic states are ordinarily treated by
antipsychotics, the therapeutic mechanisms of
antipsychotic drugs have yet been elucidated. The present study was designed to investigate the mechanisms how
antipsychotic drugs suppress the behavioral changes induced by
psychoactive drugs in mice. Low to medium doses of
methamphetamine produced hyperlocomotion, whereas high dose of
methamphetamine induced hypolocomotion. Hyperlocomotion induced by
methamphetamine was potently suppressed by
clozapine and 5-HT2 receptor antagonists, but not by the intra-accumbens injection of
haloperidol. On the other hand, microinjection of
haloperidol into the ventrolateral striatum increased locomotor activity with high dose of
methamphetamine. In contrast,
morphine-induced hyperlocomotion was suppressed by systemic as well as intra-accumbens injection of
haloperidol, whereas relatively resistant to
clozapine, compared to its effects in the case of
methamphetamine. It has been widely believed that
methamphetamine-induced
psychosis is an animal model of
schizophrenia, which is mediated by activation of accumbal
dopamine receptors. Our findings suggest that
methamphetamine differentially regulate monoaminergic systems (e.g., dopaminergic vs. 5-HTnergic), and accumbal
dopamine receptors are not involved in
methamphetamine-induced hyperlocomotion in mice. Thus, our findings may lead to a better understanding of the therapeutic mechanisms that underlie the effects of
antipsychotic drugs and behavioral effects of
methamphetamine and
morphine.